BAY 1214784Alternative Names: BAY1214784
Latest Information Update: 24 Mar 2016
At a glance
- Originator Bayer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 01 Sep 2014 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO)
- 07 Aug 2014 Preclinical trials in Undefined indication in Germany (PO)
- 07 Aug 2014 Bayer plans a phase I trial in Healthy volunteers in Germany (NCT02212080)